Metformin in acute respiratory distress syndrome: An opinion.
Exp Gerontol
; 145: 111197, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-969749
ABSTRACT
Senior individuals are more susceptible to the irreversible outcomes of endothelial barrier dysfunction, the hallmark of Acute Respiratory Distress Syndrome (ARDS). The Severe Acute Respiratory Syndrome Coronovirus 2 (SARS-CoV-2) - inflicted ARDS delivers the devastating outcomes of the COVID-19 worldwide. Endothelial hyperpermeability has been associated with both the progression and establishment of the COVID-19 - related respiratory failure. In the present study we investigated the in vitro effects of Metformin in the permeability of bovine pulmonary artery endothelial cells. Our preliminary results suggest that moderate doses (0.1, 0.5, 1.0 mM) of this anti-diabetic agent enhance the vascular barrier integrity, since it produces an increase in the transendothelial resistance of endothelial monolayers. Thus, we speculate that Metformin may deliver a new therapeutic possibility in ARDS, alone or in combination with other barrier enhancers.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Metformin
Limits:
Animals
/
Humans
Language:
English
Journal:
Exp Gerontol
Year:
2021
Document Type:
Article
Affiliation country:
J.exger.2020.111197
Similar
MEDLINE
...
LILACS
LIS